Capricor (CAPR) Narrows to Upper Limb, and the August 22 FDA Date Moves

Show 7 earlier updates

TL;DR

• The FDA confirmed on August 24 that deramiocel's PDUFA date moves to November 22, 2026, a three-month major-amendment extension off the original August 22 target. CAPR traded up more than 7% intraday to $6.75 on the news.
• Activist investor Kaos Capital is pushing Capricor's board for a cash freeze, two new directors and a strategic-alternatives committee, in a public letter sent August 21, and STAT News called deramiocel's rejection "near-certain" the day before. CAPR fell 8.04% Friday to $6.29.
• The August 22 PDUFA date in this article's title was never going to resolve on schedule, and it didn't: the FDA told Capricor on August 14 it would extend the date once a BLA amendment narrowing the label is received, and August 24's filing confirms November 22 as the new one.
• An FDA advisory panel already voted 3 for, 9 against on July 29, finding the evidence did not support the drug's effectiveness for Duchenne muscular dystrophy cardiomyopathy. The vote is non-binding.
• CAPR fell from $6.57 to $4.19 the session after the vote, a 36% one-day drop, then rallied 118% intraday on August 14 when Capricor said it would refile on a narrower label. The stock has given back most of that premarket spike and sits roughly 84% below the 52-week high of $40.37.
• The trial data itself is split. The primary endpoint, upper limb function, hit its mark at p=.029, a 54% slowing of decline. The key secondary endpoint, the heart-function measure that matters for the cardiomyopathy indication under review, missed at p=.09 once a revised statistical model was applied.
• Capricor reported Q2 2026 results on August 13: $237.9 million of cash as of June 30, down from $318.1 million at year-end 2025, which management says funds operations into Q4 2027.

When Does the FDA Decide on Deramiocel?

November 22, 2026. The original August 22 target passed without a decision, and the FDA confirmed on August 24 that the amended BLA is classified as a major amendment, which adds three months to the review clock. The August 22 target was the PDUFA date the agency assigned after accepting Capricor Therapeutics' Class 2 resubmission of the BLA for deramiocel, an allogeneic cell therapy for cardiomyopathy in Duchenne muscular dystrophy (DMD); the company disclosed it in its Q1 2026 results. The amendment narrows what is being asked for, to upper limb dysfunction only. The update at the top of this page has the sourcing.

The November 22 date will be tracked on the FDA decision calendar alongside every other PDUFA date this site follows.

This is not deramiocel's first pass through the agency. The FDA issued a Complete Response Letter in July 2025, citing insufficient evidence from the earlier HOPE-2 study, which "showed no evidence of effectiveness on skeletal or cardiac function," in the FDA's own words from its July 27 briefing documents. Capricor resubmitted on the strength of its Phase 3 HOPE-3 trial, and the FDA accepted that resubmission as complete, resuming full review.

The Board

Down 36% on the vote day, 90% off the high, ten days before the FDA's own call.

The Panel Vote and the Two Legs Down

The stock did not fall on one piece of news. It fell on two, four days apart.

July 27: the FDA posted its briefing documents ahead of the advisory committee meeting, restating that "substantial evidence of effectiveness generally requires at least two adequate and well-controlled clinical investigations, each convincing on its own," and reiterating that the earlier HOPE-2 study had not cleared that bar. The stock sold off on the release.

July 29: the Cellular, Tissue and Gene Therapies Advisory Committee met and voted 3 for, 9 against, 0 abstaining on whether the evidence supported deramiocel's effectiveness for cardiomyopathy in the narrower indication the FDA had framed for the vote, not the full label Capricor originally proposed. CEO Linda Marbán said afterward the company "remain[s] focused on working with the FDA toward potential approval" ahead of the August 22 date. The market's answer came the next session: CAPR closed at $6.57 on July 29 and $4.19 on July 30, a 36% drop in a single day.

Shares have drifted lower since, trading around $3.90-3.95 as of this week, which puts the stock roughly 90% below its 52-week high of $40.37, a level reached earlier this year on optimism around the original HOPE-3 topline readout before any of this played out.

Worth naming the parallel on this site: Replimune fell 32% on similarly skeptical FDA briefing documents in July, then rallied 127% when its own advisory panel overruled the agency's staff and voted 10-3 in favor. Capricor's setup runs the other direction. Its panel did not overrule the staff's doubts, it agreed with them, 9 to 3. That distinction matters more than the headline "another biotech advisory vote" suggests, and it's the reason I don't read this as the same trade.

A Trial That Passed One Test and Missed Another

HOPE-3 did not simply fail. It split down the middle, and which half you weight decides where you land on August 22.

The primary endpoint, Performance of Upper Limb (PUL v2.0), met its target. Deramiocel showed a 54% slowing of progression in the intent-to-treat population at 12 months, statistically significant at p=.029. The committee's own discussion of this data was, per Capricor's account, "directionally supportive."

The key secondary endpoint is where the case gets weaker. Left ventricular ejection fraction, or LVEF, is the cardiac function measure most directly tied to the cardiomyopathy indication under review, and it is the one that matters most given the drug is a cardiac cell therapy. Capricor's original topline release described a 91% slowing of LVEF decline. But an updated statistical model, developed through dialogue with the FDA and in response to peer review at The Lancet, produced a different result when applied to the overall study population: a 1.8 percentage point treatment difference at p=.09, not statistically significant. That change was disclosed in an SEC filing on July 29, the same day as the panel vote.

None of this needs an accusation of wrongdoing. The muscle data is real and the panel said so. The heart data, which is the whole point of a drug indicated for cardiomyopathy, lost its statistical footing once the analysis was redone the way regulators and peer reviewers wanted it done. A company can walk into a hearing with a genuinely positive trial and still lose the vote on the measure that was supposed to prove the label.

What Wall Street Did With Its Price Targets

Sell-side reaction to the vote was uniformly negative, and it shows in the targets, not just the ratings:

• Oppenheimer cut to Perform from Outperform.
• Cantor Fitzgerald cut to Neutral from Overweight, price target $3.50, down from $62.
• Alliance Global Partners cut to Neutral from Buy, price target $7, down from $51.
• H.C. Wainwright cut to Neutral from Buy.

These are the analysts' own targets, set in the days immediately after the vote, not this site's. A $3.50 target from Cantor sits below where the stock trades now; a $7 target from Alliance Global implies close to a double from current levels. The spread between those two numbers, both published in the same week, is itself a fair measure of how unresolved this is nine days out.

The Money Question Before the Data Question

Capricor reports Q2 2026 results and a corporate update on August 13, with the call at 4:30pm ET, one day before this article publishes and nine days before the FDA's own decision. As of March 31, 2026, the company held $278.6 million in cash, cash equivalents and marketable securities, and posted a Q1 net loss of $33.9 million. Management's stated runway, excluding any product revenue or Priority Review Voucher sale, is into Q4 2027.

That runway matters regardless of which way August 22 goes. An approval likely means a commercial launch that needs funding well before deramiocel generates meaningful revenue. A second rejection means the company reworks its regulatory strategy from a considerably weaker cash and market-cap position than it had a month ago; the market cap when this was written was roughly $225-230 million against that $278.6 million cash balance (the update at the top of this page carries the June 30 cash figure and Thursday's market cap), which is itself a signal of how little residual value the market is assigning to the drug program. Multiple shareholder class-action suits have also been filed alleging securities-fraud claims tied to the clinical data disclosures, with a lead-plaintiff deadline of September 28, 2026; those are allegations, not findings, and Capricor has not been found liable of anything.

The Options Angle

CAPR has listed options, but this site could not source verified, same-session pricing for August strikes this week, and a binary regulatory catalyst is exactly the situation where a stale or estimated option price is worse than no price at all. Rather than publish a structure against numbers that cannot be checked, the call here is a pass, logged like any other.

Trade log

#	Stance	Structure	Strikes and expiry	Cost or credit	Spot at writing	Implied move	Breakeven
1	Pass	Any directional options structure into Aug 22	N/A	Pricing not sourced this session	~$3.90-3.95 (Aug 11 close area)	Not sourced	N/A

The reasoning, for the record: a stock already down 90% with a 9-3 advisory vote against it on the record is not a coin flip priced at even odds, it is a skewed bet the market has already partly repriced. Anyone trading this into the 22nd is choosing between "the FDA sides with a panel that agreed with its own staff's doubts" and "the muscle data and the unmet medical need in DMD carry a narrow or conditional approval anyway." Both are real cases. Neither is free money, and a long straddle on an illiquid microcap biotech into a single binary date carries execution risk (wide bid-ask spreads, thin open interest) that a clean implied-move number would understate anyway.

The One-Line Read

The setup into August 22 looks more like a second rejection than a Replimune-style reversal, because here the advisory panel agreed with the FDA staff's own doubts instead of overruling them, and the specific data that failed, LVEF, is the one that was supposed to justify a cardiomyopathy label in the first place; that doesn't make CAPR a short at $3.90 with 90% of the disappointment already in the tape, but it's not a stock I'd be adding into the decision on hope that the FDA sides with the minority of its own panel.